New hybrid approach intensifies treatment for liver tumor metastases

Lisa Bodei, MD, PhD, attending physician, member, and director, RadioTheranostics Section, Molecular Imaging and Theranostics Service, Department of Radiology, Memorial Sloan Kettering Cancer Center and professor of radiology, Weill Cornell Medical College, Cornell University, New YorkResearch has shown that standard intravenous PRRT may not deliver enough radiation to these lesions. Our study explored a personalized hybrid approach-delivering the first treatments directly through hepatic arteries, followed by intravenous therapy-and sought to determine if this treatment method was feasible, safe, and effective."

The prospective pilot study included 10 patients with progressive, liver-dominant metastatic gastroenteropancreatic NETs. The patients received four cycles of ¹⁷⁷Lu-DOTATATE administered every two months: two initial intraarterial cycles followed by two intravenous cycles. Safety monitoring, radiation protection, and dosimetry comparisons between intraarterial and intravenous routes were performed and preliminary efficacy was evaluated.

The intraarterial administration procedure was feasible in 100 percent of patients. Radiation exposure to staff and patients remained within regulatory limits, with no contamination events. Dosimetry analysis indicated that intraarterial administration delivered a greater than three-fold higher radiation dose to liver metastases compared with the intravenous route.

Furthermore, ⁶⁸Ga-DOTATATE PET imaging revealed an 86 percent increase in median liver lesion uptake with intraarterial administration. Efficacy analysis showed partial response rates in 67 percent of patients at the first follow-up three months after treatment completion, improving to 87 percent at the second follow-up six months after treatment completion.

"The novelty of this research is not simply that liver-directed intraarterial PRRT increases hepatic uptake; rather, it evaluates a clinically integrated, personalized hybrid strategy that links delivery, dosimetry, safety, and response within the same prospective study," said Bodei. "For patients, this could translate into better tumor control and a more effective, individualized treatment option."

Source:

Society of Nuclear Medicine and Molecular Imaging (SNMMI)

Journal reference: